Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 691 to 700 of 1144 total matches.

In Brief: One Drop or Two

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
. Cost for 30 days' treatment, based on most recent data (April 30, 2006) from retail pharmacies ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49 |  Show IntroductionHide Introduction

Treatment of Clostridium difficile-Associated Disease (CDAD)

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006  (Issue 1247)
to bacterial resistance to metronidazole. Data on failure rates with vancomycin in patients infected ...
The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third generation cephalosporins, clindamycin and fluoroquinolones. The emergence in recent years of a new, more toxic epidemic strain (BI/NAP1), possibly related to widespread use of fluoroquinolones, has caused a marked increase in the incidence and severity of C. difficile-associated disease (CDAD).
Med Lett Drugs Ther. 2006 Nov 6;48(1247):89-90 |  Show IntroductionHide Introduction

Two New Drugs for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
AND LACTATION — Systemic exposure from ophthalmic drugs is expected to be low. There are no data on the use ...
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil (VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-20 |  Show IntroductionHide Introduction

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
vs placebo. 1. E Mignot et al. Lancet Neurol 2022; 21:125. 2. Data presented as mean values. 3. Also ...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 |  Show IntroductionHide Introduction

Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
to reduce sunburn and improve signs of photodamage in humans, but data are limited and none ...
In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild cognitive impairment or mild dementia, which was the population enrolled in the clinical trials. Now, Biogen, with the permission of the FDA, has made an addition to the labeling of the drug that says: Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical...
Med Lett Drugs Ther. 2021 Jul 26;63(1629):120 |  Show IntroductionHide Introduction

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
infection during pregnancy has not been associated with adverse maternal or fetal outcomes, but data ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Desk-Top Systems For Office Chemistries

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
; a xenon light source; a microprocessor for operations, storing data and calculating results ...
Four different desk-top systems are now widely used in physicians'; offices to measure blood chemistries. The Ektachem DT (Kodak) and Reflotron (Boehringer Mannheim), reviewed previously in The Medical Letter (volume 30, page 119, 1988; volume 31, page 90, 1989), resemble the Seralyzer (Miles Diagnostics) in cost; the Vision (Abbott), which is fully automated, is much more expensive.
Med Lett Drugs Ther. 1990 Oct 19;32(829):96-8 |  Show IntroductionHide Introduction

Oxaprozin for Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 1993  (Issue 890)
or osteoarthritis, but published data are limited. The drug’s long duration of action could provide satisfactory ...
Oxaprozin (Daypro -Searle), a propionic acid-derivative nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis and osteoarthritis. Some of the NSAIDs previously marketed in the USA are listed in the table on page 16. Ibuprofen, naproxen, fenoprofen, ketoprofen, and flurbiprofen are also propionic acid derivatives. Piroxicam and nabumetone (Medical Letter, 34:38, 1992) are also approved for once-daily use, and indomethacin is available in an extended-release formulation that can be taken once...
Med Lett Drugs Ther. 1993 Feb 19;35(890):15-6 |  Show IntroductionHide Introduction

Paclitaxel (Taxol) for Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • May 14, 1993  (Issue 896)
are usually limited to mild nausea, vomiting, diarrhea, and mucositis. In vitro data indicate, according ...
Paclitaxel (Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from the inner bark of the Western yew tree found mainly in the Pacific northwest (Taxus brevifolia). Efforts to synthesize the drug have been unsuccessful to date, but a semi-synthetic product (taxotere) prepared from the needles of European yews has shown some promise (R Pazdur et al, J Natl Cancer Inst, 89:1781, 1992), and a fungus (Taxomyces andreanae) growing on the Pacific yew was...
Med Lett Drugs Ther. 1993 May 14;35(896):39-40 |  Show IntroductionHide Introduction

Topical Terbinafine for Tinea Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 20, 1993  (Issue 903)
for treatment of tinea pedis. More data would be welcome on its effectiveness compared to other antifungals ...
Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.
Med Lett Drugs Ther. 1993 Aug 20;35(903):76-8 |  Show IntroductionHide Introduction